Treasury
3-MO 4.17% -3bp 6-MO 4.27% -6bp 1-YR 4.44% -10bp 2-YR 4.78% -10bp 3-YR 4.91% -9bp 5-YR 5.01% -8bp 7-YR 5.12% -7bp 10-YR 5.24% -5bp 20-YR 5.64% -4bp 30-YR 5.61% -3bp 3-MO 4.17% -3bp 6-MO 4.27% -6bp 1-YR 4.44% -10bp 2-YR 4.78% -10bp 3-YR 4.91% -9bp 5-YR 5.01% -8bp 7-YR 5.12% -7bp 10-YR 5.24% -5bp 20-YR 5.64% -4bp 30-YR 5.61% -3bp 3-MO 4.17% -3bp 6-MO 4.27% -6bp 1-YR 4.44% -10bp 2-YR 4.78% -10bp 3-YR 4.91% -9bp 5-YR 5.01% -8bp 7-YR 5.12% -7bp 10-YR 5.24% -5bp 20-YR 5.64% -4bp 30-YR 5.61% -3bp 3-MO 4.17% -3bp 6-MO 4.27% -6bp 1-YR 4.44% -10bp 2-YR 4.78% -10bp 3-YR 4.91% -9bp 5-YR 5.01% -8bp 7-YR 5.12% -7bp 10-YR 5.24% -5bp 20-YR 5.64% -4bp 30-YR 5.61% -3bp 3-MO 4.17% -3bp 6-MO 4.27% -6bp 1-YR 4.44% -10bp 2-YR 4.78% -10bp 3-YR 4.91% -9bp 5-YR 5.01% -8bp 7-YR 5.12% -7bp 10-YR 5.24% -5bp 20-YR 5.64% -4bp 30-YR 5.61% -3bp 3-MO 4.17% -3bp 6-MO 4.27% -6bp 1-YR 4.44% -10bp 2-YR 4.78% -10bp 3-YR 4.91% -9bp 5-YR 5.01% -8bp 7-YR 5.12% -7bp 10-YR 5.24% -5bp 20-YR 5.64% -4bp 30-YR 5.61% -3bp
US Treasury par yield curve · Oct 1 · Source: U.S. Treasury
Friday, October 2, 2026
U.S. Edition
MONEY & WORLD
Subscribe
Part B drug prices

CMS sets mandatory global-price test for selected Medicare Part B drugs from April 2027

Money & World
The Editorial Team ·
A gloved hand holds an unlabelled medicine vial beside four more vials. Stock photo
Stock photo. Not the actual scene. Photo: Thirdman / Pexels

CMS finalized a mandatory Medicare Part B drug-pricing model that will use international prices to calculate additional inflation rebates for selected drugs and biological products.

The five-year performance period starts April 1, 2027. CMS will assign beneficiaries through randomly selected geographic areas, and covered manufacturers must participate. Coinsurance can fall when the model benchmark is below the usual inflation-adjusted amount.

The rule targets qualifying single-source drugs and sole-source biological products with more than $100 million in measured Part B spending. It takes effect November 30.

CMS estimates $298 million in Original Medicare Part B net savings during the model, plus $288 million in Medicare Advantage savings and $39 million in Medicaid savings, before specified premium effects.

The document: CMS final rule, Global Benchmark for Efficient Drug Pricing Model, 91 FR 62936.

More on Personal Finance